

Paolo Mannelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6144668/publications.pdf>

Version: 2024-02-01

80
papers

2,190
citations

218677

26
h-index

254184

43
g-index

82
all docs

82
docs citations

82
times ranked

2444
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-acting injectable naltrexone for the treatment of alcohol dependence. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1265-1277.	2.8	180
2	Pre-Treatment Measures of Impulsivity, Aggression and Sensation Seeking Are Associated with Treatment Outcome for African-American Cocaine-Dependent Patients. <i>Journal of Addictive Diseases</i> , 2004, 23, 109-122.	1.3	121
3	A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 653-656.	1.4	106
4	A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia. <i>American Journal of Medicine</i> , 2007, 120, 448-454.	1.5	81
5	Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. <i>Drug and Alcohol Dependence</i> , 2017, 177, 153-162.	3.2	80
6	Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. <i>Drug and Alcohol Dependence</i> , 1994, 36, 139-145.	3.2	71
7	Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. <i>Psychopharmacology</i> , 2009, 206, 479-489.	3.1	70
8	A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome. <i>Psychosomatics</i> , 2009, 50, 78-86.	2.5	64
9	Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. <i>Drug and Alcohol Dependence</i> , 2018, 187, 79-87.	3.2	64
10	Alcohol and Drug Use Disorders Among Adults in Emergency Department Settings in the United States. <i>Annals of Emergency Medicine</i> , 2012, 60, 172-180.e5.	0.6	63
11	Prescription Pain Reliever Abuse and Dependence Among Adolescents: A Nationally Representative Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 1020-1029.	0.5	60
12	Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: A national study. <i>Journal of Psychiatric Research</i> , 2014, 50, 26-35.	3.1	56
13	Opioid use affects antioxidant activity and purine metabolism: preliminary results. <i>Human Psychopharmacology</i> , 2009, 24, 666-675.	1.5	52
14	CLINICAL STUDY: Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. <i>Addiction Biology</i> , 2009, 14, 204-213.	2.6	42
15	Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: A very low dose naltrexone and buprenorphine open label trial. <i>Drug and Alcohol Dependence</i> , 2014, 138, 83-88.	3.2	41
16	Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. <i>American Journal on Addictions</i> , 2018, 27, 177-187.	1.4	38
17	The distribution of cocaine in mice differs by age and strain. <i>Neurotoxicology and Teratology</i> , 2004, 26, 839-848.	2.4	35
18	Changes in Tobacco Smoking Following Treatment for Cocaine Dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2006, 32, 135-148.	2.1	35

#	ARTICLE	IF	CITATIONS
19	Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. <i>Drug and Alcohol Dependence</i> , 2018, 187, 171-178.	3.2	35
20	Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions. <i>Substance Abuse and Rehabilitation</i> , 2011, 2011, 77.	4.8	33
21	Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1533-1542.	2.6	32
22	Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. <i>Biological Psychiatry</i> , 2004, 56, 261-268.	1.3	31
23	Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1705-1713.	2.6	31
24	Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. <i>Psychiatric Genetics</i> , 2004, 14, 25-32.	1.1	30
25	A functional prodynorphin promoter polymorphism and opioid dependence. <i>Psychiatric Genetics</i> , 2005, 15, 295-298.	1.1	30
26	Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes. <i>Drug and Alcohol Dependence</i> , 2018, 186, 86-93.	3.2	30
27	Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. <i>Addiction</i> , 2021, 116, 1805-1816.	3.3	30
28	Medical comorbidity and alcohol dependence. <i>Current Psychiatry Reports</i> , 2007, 9, 217-224.	4.5	28
29	Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian Americans, Native Hawaiians/Pacific Islanders, and mixed-race people. <i>Journal of Psychiatric Research</i> , 2013, 47, 1940-1948.	3.1	28
30	Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. <i>European Journal of Pharmacology</i> , 2007, 565, 113-118.	3.5	27
31	Buprenorphine-Mediated Transition from Opioid Agonist to Antagonist Treatment: State of the Art and New Perspectives. <i>Current Drug Abuse Reviews</i> , 2012, 5, 52-63.	3.4	27
32	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.	2.3	27
33	Comparison of Pretreatment Characteristics and Treatment Outcomes for Alcohol-, Cocaine-, and Multisubstance-Dependent Patients. <i>Journal of Addictive Diseases</i> , 2004, 23, 93-109.	1.3	25
34	Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. <i>Psychopharmacology</i> , 2006, 185, 123-132.	3.1	25
35	Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco. <i>Drug and Alcohol Dependence</i> , 2019, 194, 468-475.	3.2	25
36	Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. <i>Substance Abuse and Rehabilitation</i> , 2011, 2011, 113.	4.8	24

#	ARTICLE	IF	CITATIONS
37	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	7.3	24
38	Serendipitous rapid detoxification from opiates: the importance of time-dependent processes. <i>Addiction</i> , 1999, 94, 589-591.	3.3	22
39	Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals. <i>Addiction Biology</i> , 2005, 10, 261-268.	2.6	22
40	Novel exonic μ -opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 133B, 105-109.	1.7	21
41	Early Outcomes Following Low Dose Naltrexone Enhancement of Opioid Detoxification. <i>American Journal on Addictions</i> , 2009, 18, 109-116.	1.4	21
42	Hallucinogen Use Disorders Among Adult Users of MDMA and Other Hallucinogens. <i>American Journal on Addictions</i> , 2008, 17, 354-363.	1.4	20
43	The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention. <i>Addictive Behaviors</i> , 2009, 34, 654-661.	3.0	19
44	Use of Very Low-Dose Naltrexone During Opiate Detoxification. <i>Journal of Addictive Diseases</i> , 2003, 22, 63-70.	1.3	18
45	The opioid overdose epidemic: opportunities for pharmacists. <i>Substance Abuse and Rehabilitation</i> , 2017, Volume 8, 53-55.	4.8	17
46	Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African-American cocaine abusers and controls. <i>Psychiatry Research</i> , 2006, 144, 99-108.	3.3	14
47	Effectiveness of Low-Dose Naltrexone in the Post-Detoxification Treatment of Opioid Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 468-474.	1.4	14
48	The Combination Very Low-Dose Naltrexone+Clonidine in the Management of Opioid Withdrawal. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 200-205.	2.1	14
49	Relationship of serum prolactin with severity of drug use and treatment outcome in cocaine dependence. <i>Psychopharmacology</i> , 2004, 176, 74-81.	3.1	13
50	Review of Popularity and Quality Standards of Opioid-Related Smartphone Apps. <i>Current Addiction Reports</i> , 2020, 7, 486-496.	3.4	13
51	Medical Symptoms Associated with Tobacco Smoking with and without Marijuana Abuse among Crack Cocaine-dependent Patients. <i>American Journal on Addictions</i> , 2005, 14, 43-53.	1.4	12
52	Methylphenidate Extended Release (OROS MPH) for the Treatment of Antidepressant-Related Sexual Dysfunction in Patients With Treatment-Resistant Depression. <i>Clinical Neuropharmacology</i> , 2009, 32, 85-88.	0.7	12
53	History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 435-441.	2.6	11
54	Zipeprol is a newly abused antitussive with an opioid spectrum and hallucinogenic effects. <i>Drug and Alcohol Dependence</i> , 1991, 27, 121-125.	3.2	9

#	ARTICLE	IF	CITATIONS
55	History of depressive and/or anxiety disorders as a predictor of treatment response: A post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 996-1002.	4.8	9
56	Trends in nonheroin opioid abuse admissions: 1992-2004. <i>Journal of Opioid Management</i> , 2007, 3, 215-223.	0.5	9
57	High- and Low-Structure Treatments for Substance Dependence: Role of Learned Helplessness. <i>American Journal of Drug and Alcohol Abuse</i> , 2003, 29, 567-584.	2.1	8
58	Antagonist Treatment of Opioid Withdrawal. <i>Journal of Addictive Diseases</i> , 2006, 25, 1-8.	1.3	8
59	Evaluating brief screeners to discriminate between drug use disorders in a sample of treatment-seeking adults. <i>General Hospital Psychiatry</i> , 2013, 35, 74-82.	2.4	8
60	Primary care for opioid use disorder. <i>Substance Abuse and Rehabilitation</i> , 2016, Volume 7, 107-109.	4.8	7
61	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	1.8	7
62	Psychological Discomfort and Mental Illness in Patients with AIDS: Implications for Home Care. <i>AIDS Patient Care and STDs</i> , 1999, 13, 555-564.	2.5	6
63	Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. <i>Journal of Psychiatric Research</i> , 2008, 42, 1213-1219.	3.1	6
64	Problem Drinking and Low-Dose Naltrexone-Assisted Opioid Detoxification. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 507-513.	1.0	6
65	Substance Use Outcomes of an Integrated HIV-Substance Use Treatment Model Implemented by Social Workers and HIV Medical Providers. <i>Health and Social Work</i> , 2016, 41, e1-e10.	1.0	6
66	Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. <i>American Journal on Addictions</i> , 2020, 29, 313-322.	1.4	6
67	The burden of caring: drug users & their families. <i>Indian Journal of Medical Research</i> , 2013, 137, 636-8.	1.0	6
68	Reduced Cannabis Use After Low-Dose Naltrexone Addition to Opioid Detoxification. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 476-478.	1.4	5
69	Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. <i>Human Psychopharmacology</i> , 2006, 21, 367-375.	1.5	4
70	Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: A novel treatment strategy. <i>Drug and Alcohol Dependence</i> , 2012, 124, 11-18.	3.2	4
71	Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. <i>American Journal on Addictions</i> , 2018, 27, 471-476.	1.4	4
72	Heroin Use in Older Adults: A Treatment Challenge. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 426-428.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. <i>American Journal on Addictions</i> , 2022, 31, 142-147.	1.4	2
74	Commentary on Winhusen <i>et al</i> . (2019): Substance use disorders, chronic diseases, and electronic health records—a paradigm for screening and intervention. <i>Addiction</i> , 2019, 114, 1471-1472.	3.3	1
75	Opioid use disorder deaths and the effects of medication therapy. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 227-229.	2.1	1
76	Family substance use screening: less to hide, more to gain. <i>Indian Journal of Medical Research</i> , 2016, 143, 682.	1.0	1
77	Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 753-759.	2.1	1
78	Reply to Dr Ng's Comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation With An Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression". <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 117-118.	1.4	0
79	Once-monthly extended-release naltrexone injections improve opioid abstinence over 24 weeks compared with placebo. <i>Evidence-Based Mental Health</i> , 2011, 14, 106-106.	4.5	0
80	Clinical epidemiology of substance use disorders: Understanding patterns, sharing knowledge, planning interventions. <i>Indian Journal of Medical Research</i> , 2019, 149, 443.	1.0	0